EiRx, BioMérieux Pen PGx Alliance to Validate Each Other’s Dx, Rx Biomarkers | GenomeWeb

EiRx, BioMérieux Pen PGx Alliance to Validate Each Other’s Dx, Rx Biomarkers

Jul 13, 2006

NEW YORK (GenomeWeb News) — EiRx Therapeutics and BioMérieux today said they plan to validate the diagnostic and therapeutic potential of their candidate tumor markers.

Terms of the alliance call for BioMérieux to see if proteins in EiRx’s biomarker panel can become components in new diagnostics for colorectal cancer. Meanwhile, EiRx will use its siRNA-driven platform to test BioMérieux’s colorectal biomarker panel as targets for new drug therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Concerns About Bias in Policies

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Reprogrammable DNA

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Lack of Diversity

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

This Week in Science

In Science this week: whole-genome sequencing of single sperm cells, and more.